Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Inspira seals Rs 1,800-crore private credit for Burger King buy in India
Inspira Global, backed by Ajanta Pharma promoters, is securing ₹1,800 crore in private credit to acquire a controlling stake in India's Burger King operator. The food business, through its arm Lenexis Foodworks, has already raised ₹1,050 crore via NCDs, with the remaining ₹800 crore anticipated this month. This significant funding signals a major move into the quick-service restaurant sector.
Nifty Pharma index up 2%; Dr Reddy's, Ajanta, Ipca, Cipla surge up to 5%
In the past seven trading days, the Nifty Pharma index outperformed the market by soaring 5.4 per cent, as compared to 0.1 per cent decline in the Nifty 50.
Stocks to watch: Ajanta Pharma, Bharti Airtel, IndiGo, NLC India, among key stocks in focus on 10 June - Mint
Stocks to watch: Ajanta Pharma, Bharti Airtel, IndiGo, NLC India, among key stocks in focus on 10 JuneMint
Stocks in news: Emcure Pharma, Dixon Technologies, Ajanta Pharma, Godrej Properties, Vedanta
Indian markets experienced a volatile session, closing higher amidst mixed signals. Bulls are defending the 23,000 level in Nifty, but uncertainty persists due to mixed heavyweight stock trends. Investors are advised to focus on stock-specific opportunities as analysts maintain a cautious outlook.
Stocks to Watch for June 10: Bharti Airtel, Indigo, Ajanta Pharma, OMC stocks and more
Bharti Airtel gains relief after the Bombay High Court quashed OTSC demands, while IndiGo remains in focus following a 10% hike in aviation turbine fuel prices. Ajanta Pharma sees a promoter stake sale via a block deal, the government expands NLC India's OFS, and Dixon Technologies plans a telecom manufacturing joint venture with Gemtek. Here are the key stocks to watch ahead of Wednesday's trading session.
Ajanta Pharma promoter sells ₹1,024 crore stake; mutual funds step in as buyers
A promoter entity of Ajanta Pharma has sold a 2.8% stake in the drugmaker for over ₹1,000 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund emerging as the key buyers.
Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MF
A promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund acquiring the stake. The transaction comes amid strong earnings growth, healthy margins and sustained momentum in the company’s pharmaceutical business.
Block deals: Four stocks see large trades worth over ₹2,000 crore on Tuesday; Check how they reacted
Barring Bluestone Jewellery, whose shares are trading with losses of over 5%, shares of Ajanta Pharma, Emcure Pharma, and Capital Small Finance Bank are trading with gains between 1% to 4% after their respective block deals on Tuesday.
Ajanta Pharma Ltd gains for third straight session
Ajanta Pharma Ltd is quoting at Rs 2993.7, up 1.56% on the day as on 12:49 IST on the NSE. The stock is up 16.43% in last one year as compared to a 6.52% jump in NIFTY and a 12.16% jump in the Nifty Pharma index.
Rajesh Palviya of Axis Sec suggests Ajanta Pharma, Tata Communications, NMDC shares to buy today - 15 May - Mint
Rajesh Palviya of Axis Sec suggests Ajanta Pharma, Tata Communications, NMDC shares to buy today - 15 MayMint
Vodafone Idea and 4 other midcap stocks hit 52-week highs, rally up to 40% in a month
Benchmark indices ended marginally higher as five BSE 150 Midcap stocks touched fresh 52-week highs, reflecting strong investor sentiment and bullish momentum. Vodafone Idea, SAIL, MCX, Laurus Labs and Ajanta Pharma recorded notable monthly gains, signalling sustained buying interest despite subdued broader market performance overall.
Ajanta Pharma Ltd spurts 1.08%, rises for third straight session
Ajanta Pharma Ltd is quoting at Rs 3125, up 1.08% on the day as on 12:49 IST on the NSE. The stock is up 20.83% in last one year as compared to a 4.86% gain in NIFTY and a 11.37% gain in the Nifty Pharma index.